Premium
Extraskeletal myxoid chondrosarcoma: A high incidence of metastatic disease to lymph nodes
Author(s) -
Claxton Matthew R.,
Reynolds Grace,
Wenger Doris E.,
Rose Peter S.,
Houdek Matthew T.
Publication year - 2020
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.26179
Subject(s) - medicine , lymph , lymph node , metastasis , incidence (geometry) , chondrosarcoma , sarcoma , oncology , radiology , pathology , cancer , physics , optics
Abstract Background Extraskeletal myxoid chondrosarcoma (ESMC) is a rare type of soft‐tissue sarcoma with limited series reporting outcome of treatment. Currently there is limited data on the incidence and impact on patient outcome in those with metastatic disease to lymph nodes in ESMC. Methods Thirty (21 males, 9 females) patients, mean age 50 ± 16 years, with ESMC were reviewed. The tumors were most commonly located in the lower extremity (n = 23, 77%) and the mean tumor size and volume were 9 ± 5 cm and 490 ± 833 cm 3 . Mean follow up was 7 ± 4 years. Results Six (20%) patients either presented (n = 3, 10%) or developed (n = 3, 10%) lymph node metastatic disease. When comparing patients without, with lymph node metastasis and metastasis elsewhere, patients with lymph nodes metastasis had worse survival than those without metastasis, however better 10‐year disease specific survival than those with metastasis elsewhere (100% vs 62% vs 0%; P < .001). Conclusion There is a high incidence of lymph node metastatic disease in patients with ESMC. Although survival in these patients is worse compared to those without metastasis, their survival is better than those with metastasis elsewhere. Due to the high incidence of lymph node metastatic disease, preoperative staging of the lymph node should be considered.